Ionis to hold first quarter 2021 financial results webcast
Ionis Pharmaceuticals (NASDAQ: IONS) will host a live webcast on May 5, 2021, at 11:30 a.m. Eastern Time to discuss its first quarter 2021 financial results and provide updates on its pipeline and business progress.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Ionis Pharmaceuticals (NASDAQ: IONS) will host a live webcast on May 5, 2021, at 11:30 a.m. Eastern Time to discuss its first quarter 2021 financial results and provide updates on its pipeline and business progress. The event will detail the company's advancements in RNA-targeted therapy and highlight its established neurological and cardiometabolic franchises. Interested parties can access the webcast through the company's investor relations website, where a replay will also be available.
Positive
- Showcasing continued leadership in RNA-targeted therapy.
- Updates on pipeline and business progress anticipated.
Negative
- None.
Details
News Market Reaction – IONS
The recorded move for IONS in the trading session of this news was +0.80%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CARLSBAD, Calif., April 21, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednesday, May 5th at 11:30 a.m. Eastern Time to discuss its first quarter 2021 financial results and report on pipeline and business progress.
Interested parties may access the webcast at https://ir.ionispharma.com/events-and-presentations/upcoming-events. A webcast replay will be available for a limited time at the same address.
About Ionis Pharmaceuticals, Inc.
For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense technology. Ionis currently has three marketed medicines and a premier late-stage pipeline highlighted by industry leading neurological and cardiometabolic franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision of becoming one of the most successful biotechnology companies.
To learn more about Ionis visit www.ionispharma.com and follow us on Twitter @ionispharma.
View original content to download multimedia:http://www.prnewswire.com/news-releases/ionis-to-hold-first-quarter-2021-financial-results-webcast-301273211.html
SOURCE Ionis Pharmaceuticals, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.